Subcutaneous Infliximab for Perianal Crohn's Disease: The BioLap-Rem Multicenter Study From the GETAID

SC IFX was effective and safe for the treatment of active pCD and for maintaining remission after switching in this large multicenter cohort, thus supporting its use in routine practice in this indication.

Authors

Institutions

Publication Details

Journal
The American Journal of Gastroenterology
Published
2025-08-28
DOI
https://doi.org/10.14309/ajg.0000000000003755
Citations
2
Primary Topic
Inflammatory Bowel Disease
Type
article
Field-Weighted Citation Impact
3.63
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Subcutaneous Infliximab for Perianal Crohn's Disease: The BioLap-Rem Multicenter Study From the GETAID

Stéphane Nahon, Pauline Wils, Stéphane Nancey, David Laharie et al.
2 citations
The American Journal of Gastroenterology
Inflammatory Bowel Disease
3.63
article

Subcutaneous Infliximab for Perianal Crohn's Disease: The BioLap-Rem Multicenter Study From the GETAID

Stéphane Nahon, Pauline Wils, Stéphane Nancey, David Laharie, Nicolas Duveau, Nadia Fathallah, Mathieu Uzzan, Driffa Moussata, Laurent Peyrin‐Biroulet, Morgane Amil, Cyrielle Giletta, Laurent Abramowitz, Mathurin Fuméry, Anthony Buisson, Lucas Guillo, Lucine Vuitton, Marc André, Philippe Seksik, Julien Kirchgesner, Nicolas Richard, Éric Vicaut, Catherine Le Berre, Maëva Charkaoui
article en
2 citations

Abstract

SC IFX was effective and safe for the treatment of active pCD and for maintaining remission after switching in this large multicenter cohort, thus supporting its use in routine practice in this indication.

The American Journal of Gastroenterology
Université Claude Bernard Lyon 1 (FR), Université de Tours (FR), Université de Bordeaux (FR), Inserm (FR), Université Paris-Est Créteil (FR), Université de Lille (FR), Paris-Est Sup (FR), Centre Hospitalier Universitaire de Bordeaux (FR), Sorbonne Université (FR), Centre Hospitalier de Roubaix (FR), Assistance Publique Hôpitaux de Marseille (FR), Centre Hospitalier Universitaire de Besançon (FR), Centre Hospitalier Universitaire de Tours (FR), Assistance Publique – Hôpitaux de Paris (FR), Clinical Investigation Center Plurithematic Tours (FR), Hospices Civils de Lyon (FR), Hôpital Saint-Antoine (FR), University of Clermont Auvergne (FR), Centre d’Investigation Clinique Innovation Technologique de Nancy (FR), Fédération Hospitalo-Universitaire, Paris Center for Microbiome Medicine (FR), Hôpital Lariboisière (FR), Hôpital Cardiologique du Haut-Lévêque (FR), Hôpital Rangueil (FR), Centre Hospitalier Universitaire de Clermont-Ferrand (FR), Hôpitaux Universitaires Henri-Mondor (FR), Institut Pierre Louis d‘Épidémiologie et de Santé Publique (FR), Centre de Recherche Saint-Antoine (FR), Hôpital Paris Saint-Joseph (FR), Maison des Sciences sociales et des Humanités de Dijon (FR), Hôpital Bichat-Claude-Bernard (FR), Centre Hospitalier Départemental Vendée (FR), Centre Hospitalier Universitaire de Rouen (FR), Hôpital Claude Huriez (FR), Groupe Hospitalier Intercommunal Le Raincy Montfermeil (FR), Périnatalité & Risques Toxiques (FR), PhysioPathologie des Adaptations Nutritionnelles (FR), Nutrition-Génétique et Exposition aux Risques Environnementaux (FR), Université Marie et Louis Pasteur (FR), Université de Picardie Jules Verne (FR), Université de Rouen Normandie (FR), Université de Franche-Comté (FR)
Openalex Percentile: Top 7%
Inflammatory Bowel Disease
3.63
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.